Description of Parkinson's disease as a clinical syndrome

被引:677
作者
Fahn, S [1 ]
机构
[1] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA
来源
PARKINSON'S DISEASE: THE LIFE CYCLE OF THE DOPAMINE NEURON | 2003年 / 991卷
关键词
Parkinson's disease; parkinsonism; Lewy body; dopamine; levodopa;
D O I
10.1111/j.1749-6632.2003.tb07458.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinsonism is a clinical syndrome comprising combinations of motor problems-namely, bradykinesia, resting tremor, rigidity, flexed posture, "freezing," and loss of postural reflexes. Parkinson's disease (PD) is the major cause of parkinsonism. PD is a slowly progressive parkinsonian syndrome that begins insidiously and usually affects one side of the body before spreading to involve the other side. Pathology shows loss of neuromelanin-containing monoamine neurons, particularly dopamine (DA) neurons in the substantia nigra pars compacta. A pathologic hallmark is the presence of cytoplasmic eosinophilic inclusions (Lewy bodies) in monoamine neurons. The loss of DA content in the nigrostriatal neurons accounts for many of the motor symptoms, which can be ameliorated by DA replacement therapy-that is, levodopa. Most cases are sporadic, of unknown etiology; but rare cases of monogenic mutations (10 genes at present count) show that there are multiple causes for the neuronal degeneration. The pathogenesis of PD remains unknown. Clinical fluctuations and dyskinesias are frequent complications of levodopa therapy; these, as well as some motor features of PD, improve by resetting the abnormal brain physiology towards normal by surgical therapy. Nonmotor symptoms (depression, lack of motivation, passivity, and dementia) are common. As the disease progresses, even motor symptoms become intractable to therapy. No proven means of slowing progression have yet been found.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 41 条
  • [1] Benamer HTS, 2000, MOVEMENT DISORD, V15, P692, DOI 10.1002/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO
  • [2] 2-V
  • [3] BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
  • [4] BERTLER A, 1959, ACTA PHYSIOL SCAND, V47, P350
  • [5] Blocq P., 1893, C R COS BIOL, V5, P105
  • [6] Brissaud E., 1895, PARIS
  • [7] CARLSSON A, 1959, PHARMACOL REV, V11, P490
  • [8] PRESENCE OF 3-HYDROXYTYRAMINE IN BRAIN
    CARLSSON, A
    LINDQVIST, M
    MAGNUSSON, T
    WALDECK, B
    [J]. SCIENCE, 1958, 127 (3296) : 471 - 471
  • [9] 3,4-DIHYDROXYPHENYLALANINE AND 5-HYDROXYTRYPTOPHAN AS RESERPINE ANTAGONISTS
    CARLSSON, A
    LINDQVIST, M
    MAGNUSSON, T
    [J]. NATURE, 1957, 180 (4596) : 1200 - 1200
  • [10] Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct
    Conway, KA
    Rochet, JC
    Bieganski, RM
    Lansbury, PT
    [J]. SCIENCE, 2001, 294 (5545) : 1346 - 1349